The Medalis research centre
Research groups
Frédéric Boisson
Molecular Imaging
Dominique Bagnard
Molecular Mechanisms and Targeted Therapeutic Intervention for Neuroprotection
Dantzer Françoise
Poly (ADP-ribosyl)ation and genome integrity
Dominique Bonnet
Integrative Chemical Biology
Sylviane Muller
Neuroimunology and peptide therapeutics
Christopher Mueller
Immune-microenvironment interaction in health and disease
Frédéric Simonin
RCPGs, Pain and inflammation
Pascal Villa
Platform of chemical biology
Sarah Cianferani
BioOrganic Mass Spectrometry
Alexandre Detappe
Nano-translational laboratory
Frédéric Bihel
Chemogenomic and Medicinal Chemistry
Alain Wagner
BioFunctional Chemistry
Medalis : an outstanding academic drugs research centre
The Medalis drugs research centre was created at the end of July 2011 in the context of the French “Investments for the Future” programme. In a context where pharmaceutical companies externalise their pre-clinical research activities to concentrate on the clinical study phases, Medalis relies on a high level of basic research to create a “pipeline” of therapeutic molecules , from the pre-clinical stage to phase II clinical trials. Medalis is the only academic drugs research centre in France to have achieved the unparalleled record of launching a new start-up every year since 2011.
Medalis in numers
7
Start-ups created
(+2 in the process)
110
Million € in cumulative funds raised
200
Research professionals employed in 12 laboratories
Therapeutic areas
Cancer
Inflammatory diseases
Pain
Nervous system diseases
Digestive system diseases
Rare diseases
Infectious diseases
Diagnostics
Les technologies de pointe
Modèle murin d’inflammation : la souris MRL/lpr
Description de la technologie/compétence
Objective: technology transfer
This interdisciplinary centre develops research projects relating to new drugs and breakthrough therapeutic innovations, by integrating technology transfer at a very early stage . The industrial clinical needs and requirements are taken into account from the stage of project conceptualisation, reducing the time required for the drugs to reach the market.
“Medalis is central to the bubbling up of new ideas, to the genesis of future therapies. The needs of the industrial partners are a key consideration in how projects are managed, which is rare in academic circles. Optimisation of the drug candidates until the pre-clinical stage allows entrepreneurs to focus their efforts on the clinical development phases through the work of the start-up.”
Pascal Neuville
CEO of Domain Therapeutics. The Alsace-based biotech is associated with two start-ups launched by Medalis.
Supporting the IMS and its centre for research, Medalis
Medalis wishes to ensure long-term employment of a group of research engineers and technicians, to create a team that is invested in an essential “memory” mission leading to model project management, ensuring rapid execution and reduced time-lines.
Consolidation of the research infrastructure also relies on support for investment in state-of-the-art equipment.